TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01122420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-Setting Tool
Description: Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Web Sites
Description: Access to publicly available health-related web sites
Study: NCT00432029

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Forearm blood flow measurement, Flow mediated dilation (FMD)
Description: Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Forearm blood flow measurement, Flow mediated dilation (FMD)
Description: Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Forearm blood flow measurement, Flow mediated dilation (FMD)
Description: Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin

Intervention type: DEVICE
Group type: OTHER
Intervention: Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light
Description: Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin

Intervention type: DEVICE
Group type: OTHER
Intervention: Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light
Description: Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin

Intervention type: DEVICE
Group type: OTHER
Intervention: Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light
Description: Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
Study: NCT04897737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIVST and enhanced adherence biofeedback
Description: The intervention includes the provision of an OraQuick HIV self-test (HIVST) for the woman and one test for each of her reported sex partners, along with instructions on how to use and interpret the results. Women were asked to report back within one month if their partner was able to test via a SMS, WhatsApp or by bringing in the test to confirm that he had tested.~Women then received adherence based feedback following the urine lateral flow assay (that measures recent tenofovir use in past 48 hours). Study counsellors requested that women provide a urine sample that was tested using the UrSure/Orasure test that provides feedback on the result in 2-3 minutes. Counselors provided counseling based on the results including how to improve daily adherence (for women without tenofovir present in their urine) and importance of condom use.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Orasure/UrSure test
Description: See above
Study: NCT00478335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: 25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitonin
Description: one nasal spray daily for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide/amiloride
Description: 25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydrochlorothiazide/amiloride
Description: 25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin
Description: 50 mg QD or 50 mg BID x 8 days depending on subject weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: indomethacin
Description: 50 mg QD or 50 mg BID x 8 days depending on subject weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for sildenafil
Description: one tablet daily for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for calcitonin
Description: one nasal spray daily
Study: NCT02667535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate
Description: Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate
Description: Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate
Description: Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate
Description: Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days.
Study: NCT03869918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Exercise at home or through a class as chosen by the subject.
Study: NCT03109704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine upper thoracic spine thrust manipulation
Description: The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Seated upper thoracic spine thrust manipulation
Description: The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust.
Study: NCT03058991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance Intervention
Description: See arm/group description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Intervention
Description: See arm/group description.
Study: NCT02406417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigation for pituitary dysfunction by blood tests.
Description: Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
Study: NCT03058991

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Informational Intervention
Description: See arm/group description.
Study: NCT01345604

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transcruciate injection of 20cc of normal saline
Description: Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
Study: NCT02406417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic function tests and pituitary imaging
Description: Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
Study: NCT01345604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcruciate injection of 20 cc of 0.5% Ropivacaine
Description: Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
Study: NCT00234858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Hyzaar) losartan/hydrochlorothiazide
Description: 50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
Study: NCT02881749

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total skin electron beam therapy (TSEBT)
Description: TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy.
Study: NCT02362308

Intervention type: OTHER
Intervention: Adrenalectomy
Description: Adrenalectomy for treatment of primary aldosteronism, according to standard of care
Study: NCT01333436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Meal
Description: During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Meal
Description: During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
Study: NCT01204957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed and Soy Protein
Description: 5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo and Soy Protein
Description: 5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
Study: NCT01296165

Intervention type: BEHAVIORAL
Intervention: Analysing the behaviours of travellers while visiting India
Description: For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value \<0.05 will be deemed to represent statistical significance.
Study: NCT02257320

Intervention type: DEVICE
Group type: OTHER
Intervention: TMJ NextGeneration(TM)
Description: The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
Study: NCT02740270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWN323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWN323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Study: NCT03829839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo nasalspray
Description: The placebo nasalspray contain identical ingredients except for the active agent itself.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The placebo pill contain identical ingredients except for the active agent itself.
Study: NCT03403088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: • Group LA
Description: to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: • Group LA-P
Description: to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: • Group DE
Description: to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: • Group DE-P
Description: to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: • Group RGI
Description: to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group RX
Description: to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity product for 20 seconds.
Study: NCT02666560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auditory Cueing
Description: Auditory cueing set at different frequency rates
Study: NCT01050855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC: Distal Campath
Description: Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
Study: NCT02881749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mechlorethamine gel 0.016%
Description: The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
Study: NCT01701713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKI ED2011

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-TDCS
Study: NCT02247258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: See arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine in case of endoscopic recurrence
Description: See arm/group descriptions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileocolonoscopy
Description: See arm/group descriptions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileocolonoscopy
Description: See arm/group descriptions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small bowel follow trough
Description: See arm/group descriptions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small bowel follow trough
Description: See arm/group descriptions
Study: NCT03554902

Intervention type: PROCEDURE
Intervention: Endoscopic gastric tubulization
Description: Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
Study: NCT01050855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC:Intermediate Campath
Description: Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC: Mini Busulfan
Description: Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
Study: NCT04857346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.
Study: NCT04551794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Selfapy with therapeutic guidance
Description: The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences with a therapeutic guide.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Selfapy with additional peer support
Description: The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
Study: NCT04213599

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary intervention
Description: Patients with STEMI undergo coronary intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary intervention
Description: Patients with STEMI undergo coronary intervention
Study: NCT02362308

Intervention type: DRUG
Intervention: mineralocorticoid receptor antagonist
Description: Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
Study: NCT02804412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: This is the control group with 14 h treatment over 10 workdays.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIAT-group
Description: Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: communication treatment group (CTG)
Description: Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
Study: NCT00337376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.